Loading stock data…
BDSX
$11.08+0.10 (+0.91%)
Market ClosedLast close May 1
Biodesix, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biodesix, Inc. in the Healthcare sector is trading at $11.08. The stock is currently 45% below its 52-week high of $20.21, remaining 14.8% above its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why BDSX maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.08
Potential Upside
5%
Whystock Fair Value$11.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$30.00+170.8%
Range$20.00 – $40.00
Fundamentals
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$117.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
1666.45%
Volume
Today's trading volume
26,407
Recent News
SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases
By Karen Roman SkylineDx said it can predict metastases and outperform existing staging systems for the country’s second most common type of skin cancer, Cutaneous Squamous Cell Carcinoma (CSCC). The results will be presented at the 22nd European Association of Dermato-Oncology Congress, held on April 23-25, 2026, in Prague and online. “This marks our first […]
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
LifeMD (LFMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
How Recent Shifts Are Reframing The Biodesix (BDSX) Investment Story
Biodesix enters this update cycle with its fair value price target holding steady at US$30.00, as the latest estimate matches the prior US$30.00 figure. That stability sits against a backdrop of mixed analyst commentary, with bullish voices pointing to an Outperform rating, stronger than expected 2026 guidance, and an improved balance sheet, while more cautious views question how durable recent execution and visibility really are. As you read on, you will see how these competing arguments...
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and near-term margin risks.